Medical treatment of amblyopia: Present state and perspectives
Abstract
A brief review is provided on the role of experimental modulation of the visual system during its plastic period. The importance of several substances could be demonstrated. Potential clinical applications of available studies for amblyopia treatment are summarised. The role of the dopaminergic system and particularly of dopamine in amblyopia are also discussed. Results of the use of cytidin-5’-diphosphocoline (citicoline) in amblyopia are evaluated in detail. Advantages and indications for a combination of citicoline with part-time occlusion are discussed in detail. Finally, new administration modalities of citicoline, more detailed evaluation of its efficacy and the use of new substances are briefly analysed.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
